According to Jazz Pharmaceuticals's latest financial reports the company's total liabilities are $7.65 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $7.65 B | -1.2% |
2022-12-31 | $7.74 B | -7.01% |
2021-12-31 | $8.33 B | 189.74% |
2020-12-31 | $2.87 B | 18.46% |
2019-12-31 | $2.42 B | -0.74% |
2018-12-31 | $2.44 B | 1.47% |
2017-12-31 | $2.41 B | -17.53% |
2016-12-31 | $2.92 B | 68.57% |
2015-12-31 | $1.73 B | -11.88% |
2014-12-31 | $1.96 B | 108.74% |
2013-12-31 | $0.94 B | 11.53% |
2012-12-31 | $0.84 B | 1290.48% |
2011-12-31 | $60.78 M | -42.21% |
2010-12-31 | $0.10 B | -41.64% |
2009-12-31 | $0.18 B | -14.33% |
2008-12-31 | $0.21 B | 37.9% |
2007-12-31 | $0.15 B | -60.97% |
2006-12-31 | $0.39 B | 38.1% |
2005-12-31 | $0.28 B |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Novartis NVS | $53.19 B | 594.78% | ๐จ๐ญ Switzerland |
AmerisourceBergen
ABC | $60.25 B | 687.00% | ๐บ๐ธ USA |
Endo International
ENDPQ | $11.73 B | 53.27% | ๐ฎ๐ช Ireland |
Teva Pharmaceutical Industries TEVA | $35.35 B | 361.75% | ๐ฎ๐ฑ Israel |